New results from a recent study on Chr. Hansen’s flagship probiotic strains Bifidobacterium BB-12® and Lactobacillus rhamnosus LGG® further emphasize Chr. Hansen’s position as the supplier of the industry’s most documented probiotic portfolio.
Combining the intake of Bifidobacterium BB-12® and Lactobacillus rhamnosus GG® with dietary counseling can reduce the risk of diabetes during pregnancy; improve blood glucose control; and may promote child health, a Finnish study concludes.
The Finnish researcher team used a randomized, controlled trial of 256 pregnant women to investigate the effect of dietary counseling and probiotics on pregnant women and their newborns (British Journal of Nutrition, 2010 Jun;103 (12):1792-9. Epub 2010 Feb 4). The study which was initiated in 2002 has so far been documented in three different publications.
Abstracts of the three publications can be found on:
“This study is good news for vendors offering probiotic supplements to pregnant women and their infants,” says Chr. Hansen’s Sune Schmoelker, Commercial Development Director, Human Health & Nutrition, and continues: “The fact that the high daily dosage of 10 billion CFU (Colony Forming Units) was well tolerated by the test subjects makes BB-12® and LGG® attractive probiotic strains for products targeted at this consumer segment – in terms of efficacy as well as safety.”
Most characterized strain
BB-12® is very likely the most thoroughly characterized probiotic strain in the world. Recently this position was further established when researchers at Chr. Hansen revealed the complete genome sequence of BB-12® in the May 2010 issue of The Journal of Bacteriology.
“This study maps the complete genome sequence of BB-12®. It is a single circular chromosome of 1,942,198 base pairs with 1,642 predicted protein coding genes, four rRNA operons and 52 tRNA genes” as Eric Johansen, Associate Vice President, Chr. Hansen explains. “Knowledge of this sequence will lead to insight into the specific features which give this strain its probiotic properties. And hopefully this will also enable us to discover new properties of BB-12®,” he ends.
With the oldest study dating back to 1986, the benefits of Chr. Hansen’s probiotics have been documented for more than two decades. “Hundreds of studies have been published on both LGG® and BB-12®. Of these, approximately 300 are human studies. These two strains are thus the most well-documented probiotic strains on the market,” Sune Schmoelker concludes.
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.